Tilray Stockholders Approve Increase In Number Of Shares To Help Drive $4B In Revenue, Stock Trades Down

Shares of cannabis giant Tilray Inc. TLRY TLRY are trading down on Friday afternoon, after the company reported that its stockholders have approved an increase in the number of authorized shares of its common stock.

As such, the cannabis company said that with additional authorized shares, it can accelerate its progress toward its goal of delivering $4 billion in revenue, a goal Tilray CEO Irwin Simon told Benzinga it intended to achieve by the end of fiscal 2024. The company is also looking to increase its retail market share from 16% to 30% by FY24 end.

Thank you Tilray Shareholders! https://t.co/1N5JQWEumj $TLRY pic.twitter.com/wL6Ev9gjpx

— Tilray (@tilray) September 10, 2021

Merger Made In Heaven

Following its merger with Aphria APHA APHA, which closed in May 2021, the new Tilray has made substantial strides across its business, by driving increased revenue through rapidly expanding its international medical business, introducing a new medical brand in Canada while increasing its share in that market, and making strong progress towards its target of $80 million in synergies.

The merger also made Tilray one of the largest cannabis companies in the world.

Tilray further intends to actively pursue accretive and strategic acquisition opportunities in the U.S., Canada, and globally, Simon said in a recent exclusive interview on Benzinga Cannabis Hour.

Encuentra nuestro contenido en Español en El Planteo:

• Acciones de Esta Empresa de Cannabis Rindieron Más que Tesla, Facebook, GE y Ford en el Último Año
• Acciones de Tilray: Analista Considera Participación en MedMen como Entrada a EEUU